TY  - JOUR
AU  - Sunny, Anjo 
AU  - Khan, M. Arif 
AU  - Mahesh, Darpelly 
AU  - Chauhan, Nikhil Singh 
AU  - Mishra, Ritu 
AU  - Presila, Namindla 
AU  - Samuel, Asa 
PY  - 2014
TI  - RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW
JF  - American Journal of Pharmacology and Toxicology
VL  - 9
IS  - 1
DO  - 10.3844/ajptsp.2014.68.74
UR  - https://thescipub.com/abstract/ajptsp.2014.68.74
AB  - The purpose of this review is to give the readers an insight about the risks and benefits of ’quinapril’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, an attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day clinical practice.